- Home
- IPHA vs LCTX Comparison
IPHA vs LCTX Comparison
Compare IPHA & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- LCTX
- Stock Information
- Founded
- IPHA 1999
- LCTX 1990
- Country
- IPHA France
- LCTX United States
- Employees
- IPHA N/A
- LCTX N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IPHA Health Care
- LCTX Health Care
- Exchange
- IPHA Nasdaq
- LCTX Nasdaq
- Market Cap
- IPHA 148.3M
- LCTX 127.7M
- IPO Year
- IPHA 2019
- LCTX N/A
- Fundamental
- Price
- IPHA $1.77
- LCTX $0.59
- Analyst Decision
- IPHA Strong Buy
- LCTX Strong Buy
- Analyst Count
- IPHA 1
- LCTX 5
- Target Price
- IPHA $11.50
- LCTX $4.80
- AVG Volume (30 Days)
- IPHA 42.3K
- LCTX 2.4M
- Earning Date
- IPHA 09-12-2024
- LCTX 03-06-2025
- Dividend Yield
- IPHA N/A
- LCTX N/A
- EPS Growth
- IPHA N/A
- LCTX N/A
- EPS
- IPHA N/A
- LCTX N/A
- Revenue
- IPHA $36,202,722.00
- LCTX $8,719,000.00
- Revenue This Year
- IPHA N/A
- LCTX N/A
- Revenue Next Year
- IPHA $101.65
- LCTX $41.15
- P/E Ratio
- IPHA N/A
- LCTX N/A
- Revenue Growth
- IPHA N/A
- LCTX N/A
- 52 Week Low
- IPHA $1.29
- LCTX $0.48
- 52 Week High
- IPHA $3.51
- LCTX $1.61
- Technical
- Relative Strength Index (RSI)
- IPHA 46.55
- LCTX 52.01
- Support Level
- IPHA $1.65
- LCTX $0.55
- Resistance Level
- IPHA $1.87
- LCTX $0.60
- Average True Range (ATR)
- IPHA 0.12
- LCTX 0.04
- MACD
- IPHA -0.03
- LCTX 0.01
- Stochastic Oscillator
- IPHA 33.47
- LCTX 83.38
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.